Investment Ratings
As per analysts rating in the last 6 months, the recommendation is to HOLD Lupin
-
Master Rating:
-
Lupin (Nse) has an operating revenue of Rs. 16,161.98 Cr. on a trailing 12-month basis. An annual revenue de-growth of -4% needs improvement, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 30 which is a POOR score indicating inconsistency in earnings, a RS Rating of 8 which is FAIR indicating the recent price performance, Buyer Demand at D- which indicates heavy supply, Group Rank of 149 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Lupin Ltd Forecast
Price Estimates
Eps And Sales Estimates
Lupin Ltd Synopsis
NSE-Medical-Generic Drugs
Lupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11055.93 Cr. and Equity Capital is Rs. 90.74 Cr. for the Year ended 31/03/2021. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.-
Market Cap
INR 39,719.43 Cr
-
Sales
INR 11,502.72 Cr
-
Shares in Float
24.07 Cr
-
No of Funds
594 K
-
Yield
0.74%
-
Book Value
2.14
-
U/D Vol Ratio
1.1
-
LTDebt/Equity
%
-
Alpha
-0.1
-
Beta
0.73
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 46.84% | 46.86% | 46.88% |
| Mutual Funds | 11.43% | 13.05% | 13.21% |
| Insurance Companies | 10.11% | 8.89% | 7.53% |
| Foreign Portfolio Investors | 18.6% | 17.87% | 18.97% |
| Financial Institutions/ Banks | 0.14% | 0.14% | 0.22% |
| Individual Investors | 9.91% | 10.02% | 10.14% |
| Others | 2.97% | 3.17% | 3.05% |
| Name | Designation |
|---|---|
| Mrs. Manju D Gupta | Chairman |
| Dr. Kamal K Sharma | Vice Chairman |
| Mr. Nilesh D Gupta | Managing Director |
| Ms. Vinita Gupta | Executive Director & CEO |
| Mr. Ramesh Swaminathan | Executive Director & Global CFO |
| Mr. Jean-Luc Belingard | Independent Director |
| Ms. Christine Mundkur | Independent Director |
| Mr. K B S Anand | Independent Director |
| Dr. Punita Kumar-Sinha | Independent Director |
| Mr. Mark D McDade | Independent Director |
Lupin Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 2798.76 | 3314.12 | 2515.96 | 2779.1 | 2990.07 |
| Operating Expenses Qtr Cr | 4269.12 | 2349.2 | 2090.91 | 2395.04 | 2444.82 |
| Operating Profit Qtr Cr | -1398.95 | 964.92 | 425.05 | 407.43 | 597.78 |
| Depreciation Qtr Cr | 129.9 | 125.36 | 125.01 | 127.08 | 125.6 |
| Interest Qtr Cr | 18.26 | 14.82 | 12.31 | 10.5 | 9.13 |
| Tax Qtr Cr | -143.31 | 203.5 | 37.44 | 73.82 | 127.91 |
| Net Profit Qtr Cr | -1329.12 | 645.87 | 316.36 | 218.25 | 360.43 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 11185.02 | 11500.85 | 11647.66 | 10211.7 | 12714.67 |
| Operating Expenses Annual Cr | 9011.87 | 9118.05 | 8503.54 | 7994.72 | 8140.08 |
| Operating Profit Annual in Cr | 2044.06 | 1907.61 | 2852.78 | 2085.86 | 4486.12 |
| Depreciation Cr | 502.83 | 518.75 | 426.3 | 389.81 | 366.11 |
| Interest Annual Cr | 40.62 | 52.59 | 35.47 | 33.24 | 29.42 |
| Tax Annual Cr | 371.08 | 324.7 | 803.54 | 449.27 | 1037.73 |
| Net Profit Annual Cr | 1258.62 | 727.55 | 1538.83 | 1344.66 | 3141.33 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | 1570.08 | 2219.49 | 3110.72 | 215.02 | 4352.09 |
| Cash from Investing Activity Annual Cr | -2507.52 | -739.56 | -2865.07 | -1159.79 | -1940.55 |
| Cash from Financing Annual Activity Cr | -53.17 | -367.85 | -295.38 | -986.98 | -160.02 |
| Net Cash Flow Annual Cr | -990.61 | 1112.08 | -49.73 | -1931.75 | 2251.52 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | 18565.52 | 17473.12 | 17117.27 | 15784.96 | 14780.24 |
| Fixed Assets Annual Cr | 4589.69 | 4335.88 | 4572.04 | 4511.7 | 3493.28 |
| Total Non Current Assets Annual Cr | 12241.19 | 9841.99 | 10205.7 | 9963.55 | 8597.47 |
| Total Current Assets Annual Cr | 9617.37 | 10838.51 | 9484.51 | 8717.45 | 9250.77 |
| Total Assets Annual Cr | 21858.56 | 20680.5 | 19690.21 | 18681 | 17848.24 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | 409.2024 | 385.72 | 378.2822 | 349.1474 | 327.286 |
| ROE Annual % | 6.77 | 4.16 | 8.98 | 8.51 | 21.25 |
| ROCE Annual % | 8.66 | 10.28 | 15.36 | 11.17 | 27.53 |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | 19.65 | 21.61 | 27.68 | 21.99 | 36.23 |
Lupin Ltd Technicals
EMA & SMA
CURRENT PRICE
873 
(-0.3)
-
- Bullish Moving Averages 0
- Bearish Moving Averages 16
EMA
-
20 Day
904.79
-
50 Day
933.01
-
100 Day
972.75
-
200 Day
1048.21
Lupin Ltd Resistance and support
875.64 PIVOT
-
First Resistance
883.57
-
Second Resistance
891.54
-
Third Resistance
899.47
-
First Support
867.67
-
Second Support
859.74
-
Third Support
851.77
-
RSI
38.49
-
MFI
35.83
-
MACD
-15.51
-
MACD signal line
-12.59
Lupin Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 1,076,029 | 47,140,830 | 43.81% |
| Week | 1,612,122 | 54,538,101 | 33.83% |
| 1 Month | 1,012,434 | 38,118,125 | 37.65% |
| 6 Month | 1,608,457 | 63,389,307 | 39.41% |
Lupin Ltd Price change analysis
-57.75
Over 1 month
Low High 863.15 959.9
-94.8
Over 3 month
Low High 863.15 995
-374.25
Over 6 months
Low High 863.15 1258.8
-41.3
Over Year
Low High 863.15 1267.65Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| Torrent Pharmaceuticals Ltd | 3,248.00 | 2,970.00 (-0.08%) | 4898 |
| Sequent Scientific Ltd | 336.40 | 161.40 (5.46%) | 382528 |
| Indoco Remedies Ltd | 529.70 | 402.45 (1.31%) | 4780 |
| FDC Ltd | 404.90 | 284.05 (-1.61%) | 13808 |
News
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)
Lupin Partners with TTP plc UK for Soft-mist Inhalation Technology Platform. Read More
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)
Disclosure pursuant to grant of 551647 options under Lupin ESOP. Read More
Lupin launches educational website Sciflix for medical stude
Sciflix is a comprehensive learning platform in pulmonology where all scientific needs of postgraduate students will be addressed by a multi Read More
LUPIN LTD. - 500257 - Announcement under Regulation 30 (LODR
Lupin launches Sciflix a mobile-friendly learning platform for post graduate students specializing in pulmonology. Read More
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)
Disclosure pursuant to allotment of 92688 shares under ESOP. Read MoreBlogs